erlotinib hydrochloride has been researched along with methimazole in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (methimazole) | Trials (methimazole) | Recent Studies (post-2010) (methimazole) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,499 | 214 | 768 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heinonen, T; Huttala, O; Mannerström, M; Sabell, E; Sarkanen, JR; Toimela, T; Ylikomi, T | 1 |
1 other study(ies) available for erlotinib hydrochloride and methimazole
| Article | Year |
|---|---|
Intra-laboratory validated human cell-based in vitro vasculogenesis/angiogenesis test with serum-free medium.
Topics: 2-Methoxyestradiol; Adipose Tissue; Aspirin; Cells, Cultured; Culture Media; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Estradiol; Human Umbilical Vein Endothelial Cells; Humans; Laboratories; Levamisole; Mannitol; Methimazole; Neovascularization, Physiologic; Reproducibility of Results; Serum; Stromal Cells; Teratogens; Toxicity Tests; Umbilical Cord; Vascular Endothelial Growth Factor A | 2017 |